IND.AU Industrial Minerals Ltd
未开盘 09-26 16:12:00 AEST
0.17
+0.00
-2.86%
最高
0.18
最低
0.17
成交量
3.33万
今开
0.18
昨收
0.18
日振幅
2.86%
总市值
1,346万
流通市值
671.75万
总股本
7,920万
成交额
5,802
换手率
0.08%
流通股本
3,951万
市净率
--
ROE
--
每股收益
0.00
52周最高
--
52周最低
--
市盈率
--
股息
--
股息收益率
--
ROA
--
分时
五日
日K
周K
月K
北京优虎网络科技有限公司
资讯
新帖
简况
【后PD-1时代重磅品种IND获受理 加科思(01167.HK)驶向快车道】智通财经APP获悉,7月10日,国家药品监督管理局药品审评中心网站显示加科思(01167.
智通财经 · 07-10
【后PD-1时代重磅品种IND获受理 加科思(01167.HK)驶向快车道】智通财经APP获悉,7月10日,国家药品监督管理局药品审评中心网站显示加科思(01167.
【石药集团(01093.HK):抗体药物偶联物SYS6023获美国临床试验批准】智通财经APP讯,石药集团(01093.HK)发布公告,集团附属公司石药集团巨石生物制药有限公司开发的抗体药物偶联物(Antibody-Drug Conjugate)SYS6023(该产品)的试验性新药(IND)申请已获美国食品药品监督管理局(FDA)批准,可以在美国开展临床试验。
智通财经 · 07-08
【石药集团(01093.HK):抗体药物偶联物SYS6023获美国临床试验批准】智通财经APP讯,石药集团(01093.HK)发布公告,集团附属公司石药集团巨石生物制药有限公司开发的抗体药物偶联物(Antibody-Drug Conjugate)SYS6023(该产品)的试验性新药(IND)申请已获美国食品药品监督管理局(FDA)批准,可以在美国开展临床试验。
【宜明昂科-B(01541.HK):国家药监局批准进行IMC-002治疗视神经脊髓炎谱系疾病的Ib/III期临床试验的新药临床试验许可】智通财经APP讯,宜明昂科-B(01541.
智通财经 · 06-21
【宜明昂科-B(01541.HK):国家药监局批准进行IMC-002治疗视神经脊髓炎谱系疾病的Ib/III期临床试验的新药临床试验许可】智通财经APP讯,宜明昂科-B(01541.
【来凯医药-B(02105.HK):中国国家药品监督管理局药品审评中心批准LAE102用于治疗肥胖症患者的新药临床试验】智通财经APP讯,来凯医药-B(02105.
智通财经 · 05-10
【来凯医药-B(02105.HK):中国国家药品监督管理局药品审评中心批准LAE102用于治疗肥胖症患者的新药临床试验】智通财经APP讯,来凯医药-B(02105.
港股异动丨来凯医药涨近12%,减肥新药临床试验申请在美获批来凯医药-B(2105.HK)盘初涨近12%报7.3港元。消息面上,公司日前发布公告称,美国食品药品监督管理局(FDA)已批准集团对于LAE102用于治疗肥胖适应症患者的新药临床试验(IND)申请,该药物是公司自主研发的针对Act-RIIA的单克隆抗体。
格隆汇 · 04-17
港股异动丨来凯医药涨近12%,减肥新药临床试验申请在美获批来凯医药-B(2105.HK)盘初涨近12%报7.3港元。消息面上,公司日前发布公告称,美国食品药品监督管理局(FDA)已批准集团对于LAE102用于治疗肥胖适应症患者的新药临床试验(IND)申请,该药物是公司自主研发的针对Act-RIIA的单克隆抗体。
【荣昌生物(09995.HK):美国食品药品监督管理局泰它西普用于治疗原发性干燥综合征快速通道认定】智通财经APP讯,荣昌生物(09995.
智通财经 · 04-02
【荣昌生物(09995.HK):美国食品药品监督管理局泰它西普用于治疗原发性干燥综合征快速通道认定】智通财经APP讯,荣昌生物(09995.
加载更多
公司概况
公司名称:
Industrial Minerals Ltd
所属市场:
ASX
上市日期:
--
主营业务:
发行价格:
--
{"stockData":{"symbol":"IND.AU","market":"AU","secType":"STK","nameCN":"Industrial Minerals Ltd","latestPrice":0.17,"timestamp":1727331120000,"preClose":0.175,"halted":0,"volume":33271,"delay":0,"floatShares":39514460,"shares":79197500,"eps":-0.018186,"marketStatus":"未开盘","marketStatusCode":0,"change":-0.005,"latestTime":"09-26 16:12:00 AEST","open":0.175,"high":0.175,"low":0.17,"amount":5802,"amplitude":0.028571,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.018186,"exchange":"ASX","tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":0,"beginTime":1727395200000},"adr":0,"adjPreClose":0.175,"openAndCloseTimeList":[[1727308800000,1727330400000]],"volumeRatio":1.2049122181159815,"nameEN":"Industrial Minerals Ltd","tradeCurrency":"AUD","lotSize":1},"requestUrl":"/m/hq/s/IND.AU","defaultTab":"news","newsList":[{"id":"2450885449","title":"【后PD-1时代重磅品种IND获受理 加科思(01167.HK)驶向快车道】智通财经APP获悉,7月10日,国家药品监督管理局药品审评中心网站显示加科思(01167.","url":"https://stock-news.laohu8.com/highlight/detail?id=2450885449","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2450885449?lang=zh_cn&edition=full","pubTime":"2024-07-10 08:49","pubTimestamp":1720572585,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["03347","BK1583","LU1169589451.USD","BK1141","BK1576","IND.AU","LU1169590202.USD","BK1161","BK4023","PD","01167","BK1574","BK7095"],"gpt_icon":0},{"id":"2449721272","title":"【石药集团(01093.HK):抗体药物偶联物SYS6023获美国临床试验批准】智通财经APP讯,石药集团(01093.HK)发布公告,集团附属公司石药集团巨石生物制药有限公司开发的抗体药物偶联物(Antibody-Drug Conjugate)SYS6023(该产品)的试验性新药(IND)申请已获美国食品药品监督管理局(FDA)批准,可以在美国开展临床试验。","url":"https://stock-news.laohu8.com/highlight/detail?id=2449721272","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2449721272?lang=zh_cn&edition=full","pubTime":"2024-07-08 17:19","pubTimestamp":1720430352,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["LU0326950275.SGD","BK1576","LU1993786604.SGD","BK1191","IE0008368742.USD","LU0880133367.SGD","BK1141","LU0067412154.USD","SG9999004220.SGD","BK1583","LU1226287529.USD","LU0072913022.USD","LU0140636845.USD","01093","BK1521","BK1515","IE00B543WZ88.USD","LU0501845795.SGD","LU1807302812.USD","IE00B5MMRT66.SGD","03347","IND.AU","BK7095"],"gpt_icon":0},{"id":"2445773728","title":"【宜明昂科-B(01541.HK):国家药监局批准进行IMC-002治疗视神经脊髓炎谱系疾病的Ib/III期临床试验的新药临床试验许可】智通财经APP讯,宜明昂科-B(01541.","url":"https://stock-news.laohu8.com/highlight/detail?id=2445773728","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2445773728?lang=zh_cn&edition=full","pubTime":"2024-06-21 18:33","pubTimestamp":1718966011,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1583","BK1576","BK1161","III","BK4134","03347","IND.AU","BK7095","01541","BK1141"],"gpt_icon":0},{"id":"2434402028","title":"【来凯医药-B(02105.HK):中国国家药品监督管理局药品审评中心批准LAE102用于治疗肥胖症患者的新药临床试验】智通财经APP讯,来凯医药-B(02105.","url":"https://stock-news.laohu8.com/highlight/detail?id=2434402028","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2434402028?lang=zh_cn&edition=full","pubTime":"2024-05-10 08:06","pubTimestamp":1715299561,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1576","CDE","BK1161","03347","IND.AU","BK1141","BK1583","02105","BK7095","BK4017"],"gpt_icon":0},{"id":"2428394673","title":"港股异动丨来凯医药涨近12%,减肥新药临床试验申请在美获批来凯医药-B(2105.HK)盘初涨近12%报7.3港元。消息面上,公司日前发布公告称,美国食品药品监督管理局(FDA)已批准集团对于LAE102用于治疗肥胖适应症患者的新药临床试验(IND)申请,该药物是公司自主研发的针对Act-RIIA的单克隆抗体。","url":"https://stock-news.laohu8.com/highlight/detail?id=2428394673","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2428394673?lang=zh_cn&edition=full","pubTime":"2024-04-17 09:33","pubTimestamp":1713317582,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["03347","BK1583","BK1161","02105","BK4585","BK1576","BK7095","IND.AU","07226","BK4588","YINN","BK1141","YANG"],"gpt_icon":0},{"id":"2424709099","title":"【荣昌生物(09995.HK):美国食品药品监督管理局泰它西普用于治疗原发性干燥综合征快速通道认定】智通财经APP讯,荣昌生物(09995.","url":"https://stock-news.laohu8.com/highlight/detail?id=2424709099","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2424709099?lang=zh_cn&edition=full","pubTime":"2024-04-02 19:07","pubTimestamp":1712056043,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK7095","III","LU1064131003.USD","BK4588","BK4134","BK1161","LU2148510915.USD","BK0239","BK1574","LU1969619763.USD","FAST","LU2328871848.SGD","09995","BK4104","BK1583","IND.AU","BK4567","688331","BK4585","LU1064130708.USD"],"gpt_icon":0}],"profile":{"stockEarnings":[{"period":"1week","weight":0},{"period":"1month","weight":-0.1053},{"period":"3month","weight":-0.1905},{"period":"6month","weight":-0.0556},{"period":"1year","weight":-0.6304},{"period":"ytd","weight":-0.7748}],"compareEarnings":[{"period":"1week","weight":0.0008},{"period":"1month","weight":-0.004},{"period":"3month","weight":0.0491},{"period":"6month","weight":0.0742},{"period":"1year","weight":0.1576},{"period":"ytd","weight":0.1513}],"compareStock":{"symbol":"F100.AU","name":"BETASHARES FTSE 100 ETF"},"yearOnYearQuotes":[{"month":1,"riseRate":0.666667,"avgChangeRate":-0.065847},{"month":2,"riseRate":0,"avgChangeRate":-0.131604},{"month":3,"riseRate":0.666667,"avgChangeRate":0.011735},{"month":4,"riseRate":1,"avgChangeRate":0.367448},{"month":5,"riseRate":0.666667,"avgChangeRate":0.129086},{"month":6,"riseRate":0.666667,"avgChangeRate":0.023554},{"month":7,"riseRate":0.25,"avgChangeRate":-0.084728},{"month":8,"riseRate":0.75,"avgChangeRate":0.032025},{"month":9,"riseRate":1,"avgChangeRate":0.40644},{"month":10,"riseRate":0.333333,"avgChangeRate":-0.057209},{"month":11,"riseRate":0.333333,"avgChangeRate":-0.13659},{"month":12,"riseRate":0,"avgChangeRate":-0.213842}],"exchange":"ASX","name":"Industrial Minerals Ltd","nameEN":"Industrial Minerals Ltd"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.28.0","shortVersion":"4.28.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Industrial Minerals Ltd(IND.AU)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Industrial Minerals Ltd(IND.AU)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Industrial Minerals Ltd,IND.AU,Industrial Minerals Ltd股票,Industrial Minerals Ltd股票老虎,Industrial Minerals Ltd股票老虎国际,Industrial Minerals Ltd行情,Industrial Minerals Ltd股票行情,Industrial Minerals Ltd股价,Industrial Minerals Ltd股市,Industrial Minerals Ltd股票价格,Industrial Minerals Ltd股票交易,Industrial Minerals Ltd股票购买,Industrial Minerals Ltd股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Industrial Minerals Ltd(IND.AU)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Industrial Minerals Ltd(IND.AU)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}